Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label single-arm study of FCN-159 in neurofibromatosis type 1 with plexiform neurofibromas requiring systemic therapy
CTR20202330Phase 2Completed
- Sponsor
- Fosun Pharma
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by Fosun Pharma. Started Mar 2021; status: completed.
02
Drugs
luvometinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on CTR20202330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202330.